 MIAMI, Oct. 13, 2022 GLOBE NEWSWIRE -- Veru Inc. NASDAQ: VERU, a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that data from the Phase 3 trial of sabizabulin for hospitalized moderate to severe COVID-19 patients who required supplemental oxygen has been accepted as a late-breaker oral presentation at the upcoming IDWeek Infectious Disease Week 2022 taking place October 19-23, 2022, in Washington, D.C. 